• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.参与抗肿瘤免疫的基因的mRNA表达水平:与肌肉浸润性膀胱癌预后相关的三基因特征的鉴定
Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.
2
: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer.一种预测非肌层浸润性膀胱癌进展风险的新型分子标志物。
Oncol Lett. 2019 Oct;18(4):3471-3480. doi: 10.3892/ol.2019.10706. Epub 2019 Aug 2.
3
Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.膀胱尿路上皮癌中免疫检查点相关分子的信使核糖核酸表达与蛋白质表达的相关性:一项回顾性研究。
Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.
4
microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.大量膀胱肿瘤中 microRNA 表达谱:鉴定与肌层浸润性膀胱癌侵袭性相关的 3 个 miRNA 特征。
Int J Cancer. 2013 Jun 1;132(11):2479-91. doi: 10.1002/ijc.27949. Epub 2013 Feb 25.
5
History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.肌层浸润性膀胱癌病史可能对接受根治性膀胱切除术治疗的 cT2-4aN0M0 膀胱癌患者的预后产生更差的影响。
Clin Genitourin Cancer. 2018 Oct;16(5):e969-e976. doi: 10.1016/j.clgc.2018.04.004. Epub 2018 Apr 28.
6
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术(re-cTURBT)作为pT1期高级别(HG)疾病复发和进展的风险指标是否有用?一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
7
Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.非肌肉浸润性膀胱癌和肌肉浸润性膀胱癌预后和差异表达基因的比较生物信息学分析。
J Proteomics. 2020 Oct 30;229:103951. doi: 10.1016/j.jprot.2020.103951. Epub 2020 Aug 27.
8
Utility of SAM68 in the progression and prognosis for bladder cancer.SAM68在膀胱癌进展和预后中的作用
BMC Cancer. 2015 May 6;15:364. doi: 10.1186/s12885-015-1367-x.
9
Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker.大规模实时逆转录-PCR 方法检测人膀胱癌血管生成途径:鉴定 VEGFA 为主要独立预后标志物。
Eur Urol. 2009 Oct;56(4):678-88. doi: 10.1016/j.eururo.2008.05.027. Epub 2008 May 23.
10
In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.在pT1期非肌层浸润性膀胱癌(NMIBC)中,高KRT20和低KRT5 mRNA表达可识别管腔亚型,并预测复发和生存情况。
Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10.

引用本文的文献

1
Review of BCG immunotherapy for bladder cancer.卡介苗免疫疗法治疗膀胱癌的综述。
Clin Microbiol Rev. 2025 Mar 13;38(1):e0019423. doi: 10.1128/cmr.00194-23. Epub 2025 Feb 11.
2
Modelling the tumor immune microenvironment for precision immunotherapy.构建肿瘤免疫微环境模型以实现精准免疫治疗。
Clin Transl Immunology. 2022 Jun 26;11(6):e1400. doi: 10.1002/cti2.1400. eCollection 2022.
3
A Novel Immune-Gene Pair Signature Revealing the Tumor Microenvironment Features and Immunotherapy Prognosis of Muscle-Invasive Bladder Cancer.一种揭示肌层浸润性膀胱癌肿瘤微环境特征和免疫治疗预后的新型免疫基因对特征
Front Genet. 2021 Nov 26;12:764184. doi: 10.3389/fgene.2021.764184. eCollection 2021.
4
Immunoregulated insulitis and slow-progressing type 1 diabetes after duodenopancreatectomy.十二指肠胰切除术后免疫调节性胰岛炎与缓慢进展的1型糖尿病
Diabetologia. 2021 Dec;64(12):2731-2740. doi: 10.1007/s00125-021-05563-8. Epub 2021 Sep 14.
5
Identification of 9-Core Immune-Related Genes in Bladder Urothelial Carcinoma Prognosis.膀胱癌预后中9个核心免疫相关基因的鉴定
Front Oncol. 2020 Jul 8;10:1142. doi: 10.3389/fonc.2020.01142. eCollection 2020.
6
Establishment and Validation of an Individualized Cell Cycle Process-Related Gene Signature to Predict Cancer-Specific Survival in Patients with Bladder Cancer.建立和验证个体化细胞周期相关基因特征以预测膀胱癌患者的癌症特异性生存
Cancers (Basel). 2020 May 2;12(5):1146. doi: 10.3390/cancers12051146.
7
Identification of a 13‑mRNA signature for predicting disease progression and prognosis in patients with bladder cancer.鉴定 13 个 mRNA 标志物,用于预测膀胱癌患者的疾病进展和预后。
Oncol Rep. 2020 Feb;43(2):379-394. doi: 10.3892/or.2019.7429. Epub 2019 Dec 12.
8
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.抑制PI3K通路可增加肌层浸润性膀胱癌中的免疫浸润。
Oncoimmunology. 2019 Mar 16;8(5):e1581556. doi: 10.1080/2162402X.2019.1581556. eCollection 2019.

本文引用的文献

1
Changes in Immunogenicity during the Development of Urinary Bladder Cancer: A Preliminary Study.膀胱癌发生发展过程中的免疫原性变化:一项初步研究。
Int J Mol Sci. 2016 Feb 25;17(3):285. doi: 10.3390/ijms17030285.
2
Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal.手术切除前后外周血中CD4+CD25+Foxp3+细胞频率与膀胱癌恶性指标的关系
Oncotarget. 2016 Mar 8;7(10):11450-62. doi: 10.18632/oncotarget.7199.
3
Rationale for anti-OX40 cancer immunotherapy.抗OX40癌症免疫疗法的原理。
Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30.
4
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.一种源自患者的泛癌上皮-间质转化特征可识别上皮-间质转化后的整体分子改变和免疫靶点富集。
Clin Cancer Res. 2016 Feb 1;22(3):609-20. doi: 10.1158/1078-0432.CCR-15-0876. Epub 2015 Sep 29.
5
The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8 T cell responses.检查点抑制剂TIGIT会限制抗肿瘤和抗病毒CD8 T细胞反应。
Oncoimmunology. 2015 May 27;4(9):e1036214. doi: 10.1080/2162402X.2015.1036214. eCollection 2015 Sep.
6
The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer.肿瘤浸润淋巴细胞亚群在膀胱癌中的预后作用。
World J Urol. 2016 Feb;34(2):181-7. doi: 10.1007/s00345-015-1615-3. Epub 2015 Jun 9.
7
Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?用于泌尿系统癌症的免疫检查点抑制剂:只是冰山一角?
Eur Urol. 2015 Aug;68(2):280-2. doi: 10.1016/j.eururo.2015.03.022. Epub 2015 Mar 21.
8
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.免疫受体 TIGIT 调节抗肿瘤和抗病毒 CD8(+) T 细胞效应功能。
Cancer Cell. 2014 Dec 8;26(6):923-937. doi: 10.1016/j.ccell.2014.10.018. Epub 2014 Nov 26.
9
Shaping of an effective immune microenvironment to and by cancer cells.癌细胞对有效免疫微环境的塑造以及受其塑造。
Cancer Immunol Immunother. 2014 Oct;63(10):991-7. doi: 10.1007/s00262-014-1590-3. Epub 2014 Aug 12.
10
CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.直肠癌放化疗前后CD8 +和FOXP3 +肿瘤浸润性T细胞
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S414-21. doi: 10.1245/s10434-014-3584-y. Epub 2014 Feb 25.

参与抗肿瘤免疫的基因的mRNA表达水平:与肌肉浸润性膀胱癌预后相关的三基因特征的鉴定

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

作者信息

Le Goux Constance, Vacher Sophie, Pignot Géraldine, Sibony Mathilde, Barry Delongchamps Nicolas, Terris Benoit, Piaggio Eliane, Zerbib Marc, Damotte Diane, Bieche Ivan

机构信息

Department of Genetic, Institut curie, Unité de pharmacogénomique, Service de génétique, Paris, France.

Department of Urology, Institut Paoli-Calmettes, Service d'Urologie, Marseille, France.

出版信息

Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

DOI:10.1080/2162402X.2017.1358330
PMID:29147616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5674963/
Abstract

Immunotherapy for bladder cancer has given promising results. Here we aimed to evaluate the possible involvement and prognostic value of 33 genes involved in the immune response during bladder carcinogenesis. Expression levels were assessed by quantitative real-time RT-PCR in normal and tumor human bladder samples. Immunohistochemistry was performed to evaluate the protein expression of 2 genes and relation of the mRNA and protein levels was analyzed. Tumors were obtained from 154 patients (83 with muscle-invasive bladder cancer [MIBC] and 71 non-MIBC [NMIBC]) who underwent transurethral bladder resection or radical cystectomy between 2002 and 2006. All patients signed an informed consent. Results of molecular analyses were coupled with survival analyses. Overall, 25 genes (75.8%) were significantly overexpressed in MIBC and 15 (45.5%) were deregulated in NMIBC as compared with normal tissue. On multivariate analysis, risk of NMIBC recurrence was increased with high / ratio and overexpression of (p = 0.016 and p = 0.0039, respectively). In MIBC, a molecular signature of 3 genes () was significantly associated with prognosis in terms of recurrence-free and overall survival (p = 0.0007 and p = 0.007). RT-PCR findings were confirmed by immunohistochemistry for CD8 and FOXP3, with high association between mRNA and protein levels. Finally, risk of recurrence of non-muscle-invasive bladder cancer was increased with high / ratio and overexpression. We identified a 3 gene molecular signature associated with prognosis of muscle-invasive bladder cancer. These results confirm the useful role of immune checkpoints in bladder carcinogenesis and suggest targets for therapy.

摘要

膀胱癌免疫疗法已取得了令人鼓舞的成果。在此,我们旨在评估33个参与膀胱癌发生过程中免疫反应的基因的可能作用及预后价值。通过定量实时逆转录聚合酶链反应(RT-PCR)评估正常和肿瘤人类膀胱样本中的基因表达水平。进行免疫组织化学以评估2个基因的蛋白表达,并分析mRNA和蛋白水平之间的关系。肿瘤样本来自2002年至2006年间接受经尿道膀胱切除术或根治性膀胱切除术的154例患者(83例肌层浸润性膀胱癌[MIBC]和71例非肌层浸润性膀胱癌[NMIBC])。所有患者均签署了知情同意书。分子分析结果与生存分析相结合。总体而言,与正常组织相比,25个基因(75.8%)在MIBC中显著过表达,15个基因(45.5 %)在NMIBC中表达失调。多因素分析显示,NMIBC复发风险随着高 / 比值和 的过表达而增加(分别为p = 0.016和p = 0.0039)。在MIBC中,3个基因( )的分子特征在无复发生存率和总生存率方面与预后显著相关(p = 0.0007和p = 0.007)。RT-PCR结果通过CD8和FOXP3的免疫组织化学得到证实,mRNA和蛋白水平之间具有高度相关性。最后,非肌层浸润性膀胱癌的复发风险随着高 / 比值和 的过表达而增加。我们确定了一个与肌层浸润性膀胱癌预后相关的3基因分子特征。这些结果证实了免疫检查点在膀胱癌发生中的重要作用,并提示了治疗靶点。